Connor, Clark & Lunn Investment Management Ltd. Precision Biosciences Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.97 - $45.0 $30,267 - $1.4 Million	-31,204 Reduced 26.72%	85,573 $101,000
Q3 2022 Nov 10, 2022	BUY	$1.22 - $40.8 $17,843 - $596,740	14,626 Added 14.32%	116,777 $152,000
Q2 2022 Aug 05, 2022	BUY	$1.15 - $3.34 $104,099 - $302,340	90,521 Added 778.34%	102,151 $163,000
Q1 2022 May 12, 2022	BUY	$2.96 - $7.76 $1,145 - $3,003	387 Added 3.44%	11,630 $36,000
Q4 2021 Feb 10, 2022	SELL	$7.4 - $11.66 $1,768 - $2,786	-239 Reduced 2.08%	11,243 $83,000
Q3 2021 Nov 12, 2021	BUY	$9.18 - $14.15 $105,404 - $162,470	11,482 New	11,482 $133,000

Others Institutions Holding DTIL

# of Institutions

Shares Held

2.56M

Call Options Held

Put Options Held

View Full List

About PRECISION BIOSCIENCES INC

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

More about DTIL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account